Universal Display Corporation — Q1 2024 Form 10-Q Summary
Business context and reporting period
Universal Display develops and commercializes OLED technologies, materials, intellectual property and manufacturing processes for display and lighting applications. Revenue is generated primarily from OLED material sales, royalty and license fees, technology development and support, and Adesis contract research services. This unaudited report covers the three months ended March 31, 2024, compared with the three months ended March 31, 2023.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenue | $165.3 million | $130.5 million | +26.7% |
| Material sales | $93.3 million | $70.2 million | +32.9% |
| Royalty and license fees | $68.3 million | $55.2 million | +23.7% |
| Contract research services | $3.7 million | $5.1 million | -26.8% |
| Gross profit | $128.3 million | $97.5 million | +31.6% |
| Gross margin | 77.6% | 74.7% | +2.9 percentage points |
| Operating income | $62.9 million | $45.4 million | +38.6% |
| Net income | $56.9 million | $39.8 million | +42.7% |
| Diluted EPS | $1.19 | $0.83 | +43.4% |
| Operating cash flow | $72.2 million | $47.6 million | +51.5% |
Research and development expense increased 20.9% to $38.0 million, primarily due to higher employee-related costs, PPG development activity and contract research costs. Selling, general and administrative expense increased 25.0% to $19.3 million. Amortization increased to $4.5 million from $2.9 million following the April 2023 Merck KGaA patent acquisition. Royalty and license expense included a $1.5 million one-time expense related to an amendment to an academic license agreement.
Interest income increased to $9.6 million from $7.0 million because of higher investment yields and investment balances. The effective tax rate declined to 19.4% from 22.8%, primarily because of changes involving Chinese withholding-tax credits and capitalization rules for research and development expenses.
At March 31, 2024, cash and cash equivalents were $74.0 million, short-term investments were $465.3 million and long-term U.S. government bond investments were $298.9 million, totaling $838.2 million of cash and investments. Working capital was $826.3 million. The filing does not disclose outstanding borrowings or traditional debt; liabilities included $25.5 million of present-value operating lease obligations and $52.6 million of retirement plan benefit liabilities.
Investing activities used $64.2 million, including net investment purchases and $7.2 million of capital expenditures. Financing activities used $25.9 million, including $19.5 million of common-stock dividends and $7.1 million of employee tax withholding payments. The quarterly dividend was $0.40 per share, and the board declared another $0.40 per-share dividend payable June 28, 2024.
Material changes versus the prior comparable period
- Material sales increased 33%, with unit material volume increasing 37%; green emitter sales rose to $70.8 million and red emitter sales rose to $20.6 million.
- Royalty and license fees increased 24%, supported primarily by higher unit material volume.
- Gross margin expanded to 78% from 75%, helped by higher OLED-related revenue and a $3.3 million reduction in inventory reserve expense.
- Operating income and net income grew faster than revenue despite increased research, administrative, amortization and royalty expenses.
- Contract research services revenue declined 27% because of reduced demand from several Adesis customers.
- The prior-year revenue comparison included a $5.7 million favorable cumulative catch-up adjustment, while Q1 2024 included a $0.5 million reduction from such adjustments.
- Cash and investments increased by approximately $38.6 million from December 31, 2023, although cash and cash equivalents alone declined by $18.0 million because of investment purchases, dividends and employee tax payments.
Guidance, outlook, risks and unusual items
Management did not provide a specific quarterly or full-year revenue or earnings forecast in the filing. Management stated that existing cash, cash equivalents and short-term investments are expected to be sufficient to meet obligations for at least the next twelve months, based on internal forecasts and assumptions.
- Results may fluctuate based on OLED material volumes, timing of license and royalty receipts, research and development and patent spending, and new business relationships.
- Customer concentration is significant: three customers represented 41%, 25% and 16% of Q1 2024 revenue, respectively. Approximately 98% of revenue was generated outside North America.
- The company depends substantially on one chemical-material supplier and has $29.7 million of inventory purchase commitments under its PPG agreement. The PPG agreement runs through December 31, 2024 and automatically renews annually unless terminated with advance notice.
- A $57.8 million long-term Korean withholding-tax receivable depends on ongoing litigation against the Korean National Tax Service. The company recorded a related $15.7 million long-term U.S. tax liability and recognized $2.3 million of foreign-exchange loss from remeasurement during the quarter.
- The company has patent challenges and opposition proceedings in the ordinary course. The filing states that no material changes occurred to previously disclosed risk factors.
- Inventory valuation, revenue estimates over long-term contracts, tax recoverability, investments, stock compensation and retirement obligations require significant management judgment.
- The company is expanding manufacturing capacity in Shannon, Ireland; operations began in June 2022 and the facility is expected to eventually double production capacity and diversify manufacturing.
Important facts for investors to verify
- Whether the Q1 increase in OLED material volumes and customer demand persists through the remainder of 2024.
- The sustainability of the 77.6% gross margin amid product mix, pricing, manufacturing costs and customer contract estimates.
- Customer concentration, particularly the exposure represented by the three largest customers and South Korean revenue.
- The timing and ultimate recoverability of the $57.8 million Korean tax receivable and related tax obligations.
- Progress, spending and capacity utilization at the Shannon manufacturing facility.
- Future effects of the Merck KGaA patent acquisition, including annual amortization and related intellectual-property benefits.
- Adesis demand trends, PPG supply commitments and potential inventory-obsolescence charges.
- The company’s reliance on investment income and the sensitivity of liquidity returns to interest rates.